AI support for faster, more confident skin cancer assessments
Dermalyser
General Practitioner
23
Dermatologist
10
Dermalyser
5
As a primary care doctor, you face difficult choices when assessing suspicious skin lesions. Dermalyser is a CE-marked app that provides AI-driven decision support in just seconds, by analysing a dermoscopic image captured with your smartphone. Our goal is to support you — not replace you — by improving confidence, reducing unnecessary referrals, and reassuring patients.
Reliable AI support, built on clinical validation and real-world evidence.- Faster decisions – AI support in seconds, right in the consultation.
- Fewer unnecessary referrals – Improves efficiency and reduces patient anxiety.
Step 1, Download and get started
Install the Dermalyser app on your smartphone. Works on both iOS and Android.
Step 2, One Image
Attach your dermatoscope, take a dermoscopic image, and upload it securely.
Step 3, Receive instant diagnostic support
Dermalyser analyses the image in seconds and provides AI-driven decision support to guide your next step.
I believe the app will make skin tumour management in primary care safer and more efficient, reducing unnecessary referrals and excisions while supporting GPs with greater diagnostic confidence.
Magnus Falk
Principal Investigator
Supporting Melanoma Assessment with AI
For many GPs, assessing suspicious skin lesions is one of the most challenging parts of daily practice. Subtle features of melanoma are easily missed, and the pressure of limited consultation time adds to the difficulty. Dermalyser fits seamlessly into this workflow.Dermalyser is designed to support this process. By analysing dermoscopic images in just seconds — evidence-based, CE-marked, it provides clinically validated decision support that complements your judgement — helping you feel more confident in difficult cases, reduce unnecessary referrals, and reassure patients quickly.
AUC Performance in Melanoma Detection
Dermalyser
0.96
Expert dermatologist
0.85
General practitioner
0.70
AUC Performance in Melanoma Detection
Clinically Proven Accuracy. In clinical evaluation, Dermalyser reached an AUC score of 0.96, confirming strong performance in melanoma detection. This high level of accuracy is designed to support GPs in everyday practice, providing fast and reliable decision support that complements — never replaces — clinical expertise. "Backed by rigorous trials, CE-marked approval, and a study published in the British Journal of Dermatology, Dermalyser provides evidence-based decision support you can trust. Learn more in our clinical studies.